You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAminophylline
Accession NumberDB01223  (APRD00329)
TypeSmall Molecule
GroupsApproved
Description

Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.

Structure
Thumb
Synonyms
SynonymLanguageCode
AminophyllinNot AvailableNot Available
SomophyllinNot AvailableNot Available
Theophylline ethylenediamineNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aminophyllinetablet100 mgoralWest ward Pharmaceutical Corp1975-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllinetablet200 mgoralWest ward Pharmaceutical Corp1976-05-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousHospira, Inc.1983-10-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousHospira, Inc.1983-10-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousHospira, Inc.1983-10-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousHospira, Inc.1983-10-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousHospira, Inc.1983-10-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousGeneral Injectables & Vaccines, Inc.2009-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousCardinal Health2011-02-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aminophyllineinjection, solution25 mg/mLintravenousCardinal Health2011-02-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
MinomalNot Available
PhyllocontinNot Available
SomophyllinNot Available
TruphyllineNot Available
Brand mixtures
Brand NameIngredients
Ami-Nesine LiqAminophylline + Guaifenesin
Quiex - Forte SyrAminophylline + Guaifenesin
Quiex LiqAminophylline + Guaifenesin
Quiex-K1 SyrAminophylline + Guaifenesin + Potassium Iodide
Quiex-Pred SusAminophylline + Guaifenesin + Prednisolone
SaltsNot Available
Categories
CAS number317-34-0
WeightAverage: 420.4264
Monoisotopic: 420.198199306
Chemical FormulaC16H24N10O4
InChI KeyFQPFAHBPWDRTLU-UHFFFAOYSA-N
InChI
InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
IUPAC Name
bis(1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione); ethane-1,2-diamine
SMILES
NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkaloids and derivatives. These are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic properties. Also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentAlkaloids and derivatives
Alternative Parents
Substituents
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Pyrimidone
  • Pyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic heteropolycyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
PharmacodynamicsAminophylline is the ethylenediamine salt of theophylline. Theophylline stimulates the CNS, skeletal muscles, and cardiac muscle. It relaxes certain smooth muscles in the bronchi, produces diuresis, and causes an increase in gastric secretion.
Mechanism of actionAminophylline is the ethylenediamine salt of theophylline. After ingestion, theophylline is released from aminophylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
AbsorptionNot Available
Volume of distribution
  • 0.3 to 0.7 L/kg
Protein binding60%
MetabolismNot Available
Route of eliminationNot Available
Half life7-9 hours
Clearance
  • 0.29 mL/kg/min [postnatal age 3-15 days]
  • 0.64 mL/kg/min [postnatal age 25-57 days]
  • 1.7 mL/kg/min [ 1-4 years]
  • 1.6 mL/kg/min [4-12 years]
  • 0.9 mL/kg/min [13-15 years]
  • 1.4 mL/kg/min [16-17 years]
  • 0.65 mL/kg/min [Adults (16-60 years), non-smoking asthmatics]
  • 0.41 mL/kg/min [Elderly (>60 years). liver, and renal function]
  • 0.33 mL/kg/min [Acute pulmonary edema]
  • 0.54 mL/kg/min [COPD→60 years, stable non-smoker >1 year]
  • 0.48 mL/kg/min [COPD with cor pulmonale]
  • 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
  • 0.31 mL/kg/min [Liver disease -cholestasis]
  • 0.35 mL/kg/min [cirrhosis]
  • 0.65 mL/kg/min [acute hepatitis]
  • 0.47 mL/kg/min [Sepsis with multi-organ failure]
  • 0.38 mL/kg/min [hypothyroid]
  • 0.8 mL/kg/min [hyperthyroid]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9778
Blood Brain Barrier+0.5908
Caco-2 permeable-0.6802
P-glycoprotein substrateSubstrate0.7341
P-glycoprotein inhibitor INon-inhibitor0.9164
P-glycoprotein inhibitor IINon-inhibitor0.9673
Renal organic cation transporterNon-inhibitor0.7935
CYP450 2C9 substrateNon-substrate0.8073
CYP450 2D6 substrateNon-substrate0.8093
CYP450 3A4 substrateSubstrate0.5482
CYP450 1A2 substrateNon-inhibitor0.8726
CYP450 2C9 substrateNon-inhibitor0.9332
CYP450 2D6 substrateNon-inhibitor0.9633
CYP450 2C19 substrateNon-inhibitor0.9184
CYP450 3A4 substrateNon-inhibitor0.8031
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8858
Ames testNon AMES toxic0.6724
CarcinogenicityNon-carcinogens0.8696
BiodegradationNot ready biodegradable0.9149
Rat acute toxicity2.4979 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7876
hERG inhibition (predictor II)Inhibitor0.6143
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous25 mg/mL
Tabletoral100 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Aminophylline 250 mg/10 ml vial0.48USD ml
Aminophylline 25 mg/ml0.41USD ml
Phyllocontin-350 350 mg Sustained-Release Tablet0.31USD tablet
Aminophylline 100 mg tablet0.26USD tablet
Phyllocontin 225 mg Sustained-Release Tablet0.24USD tablet
Aminophylline powder0.17USD g
Aminophylline 200 mg tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility2E+005 mg/LMERCK INDEX (1996)
logP-3.03Not Available
Predicted Properties
PropertyValueSource
logP-0.77ChemAxon
pKa (Strongest Acidic)7.82ChemAxon
pKa (Strongest Basic)-0.78ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area69.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity44.93 m3·mol-1ChemAxon
Polarizability16.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesR03DA05
AHFS Codes
  • 86:16.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
AcebutololMay enhance the adverse/toxic effect of other Sympathomimetics.
AdalimumabMay decrease the serum concentration of Theophylline Derivatives.
AdenosineTheophylline Derivatives may diminish the therapeutic effect of Adenosine.
AllopurinolMay increase the serum concentration of Theophylline Derivatives.
AlprazolamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
AminoglutethimideMay increase the metabolism of Theophylline Derivatives.
AmphetamineMay enhance the adverse/toxic effect of other Sympathomimetics.
AprepitantMay increase the serum concentration of CYP3A4 Substrates.
AtomoxetineMay enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.
BatimastatMay decrease the serum concentration of Theophylline Derivatives. Exceptions: Fosamprenavir.
BenzphetamineMay enhance the adverse/toxic effect of other Sympathomimetics.
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
BromazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ButabarbitalMay decrease the serum concentration of Theophylline Derivatives.
ButethalMay decrease the serum concentration of Theophylline Derivatives.
CalcidiolMay increase the serum concentration of Theophylline Derivatives.
CalcitriolMay increase the serum concentration of Theophylline Derivatives.
CamazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
CarbamazepineTheophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.
CarbimazoleMay increase the serum concentration of Theophylline Derivatives.
ChlordiazepoxideTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ChlormezanoneTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ChlorphentermineMay enhance the adverse/toxic effect of other Sympathomimetics.
CholecalciferolMay increase the serum concentration of Theophylline Derivatives.
CimetidineMay decrease the metabolism of Theophylline Derivatives.
CinolazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ClenbuterolMay enhance the adverse/toxic effect of other Sympathomimetics.
ClobazamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ClonazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ClotiazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
CloxazolamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DihydrotachysterolMay increase the serum concentration of Theophylline Derivatives.
DisulfiramMay increase the serum concentration of Theophylline Derivatives.
DobutamineMay enhance the adverse/toxic effect of other Sympathomimetics.
DopamineMay enhance the adverse/toxic effect of other Sympathomimetics.
EpinephrineMay enhance the adverse/toxic effect of other Sympathomimetics.
ErgocalciferolMay increase the serum concentration of Theophylline Derivatives.
EthanolAlcohol (Ethyl) may increase the serum concentration of Aminophylline.
FebuxostatMay increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated.
FenoterolMay enhance the adverse/toxic effect of other Sympathomimetics.
FludiazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
FlunitrazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
FluvoxamineMay decrease the metabolism of Theophylline Derivatives.
FormoterolTheophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.
FosaprepitantMay increase the serum concentration of CYP3A4 Substrates.
FosphenytoinTheophylline Derivatives may decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Theophylline Derivatives.
HalazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
HeptabarbitalMay decrease the serum concentration of Theophylline Derivatives.
HexobarbitalMay decrease the serum concentration of Theophylline Derivatives.
IndacaterolTheophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol.
IsoflurophateMay decrease the serum concentration of Theophylline Derivatives. Exceptions: Fosamprenavir.
IsoniazidMay increase the serum concentration of Theophylline Derivatives.
IsoprenalineMay enhance the adverse/toxic effect of other Sympathomimetics.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
KetazolamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
LabetalolMay enhance the adverse/toxic effect of other Sympathomimetics.
LinezolidMay enhance the hypertensive effect of Sympathomimetics.
LithiumTheophylline Derivatives may decrease the serum concentration of Lithium.
LorazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
MephentermineMay enhance the adverse/toxic effect of other Sympathomimetics.
MetaraminolMay enhance the adverse/toxic effect of other Sympathomimetics.
MethamphetamineMay enhance the adverse/toxic effect of other Sympathomimetics.
MethimazoleMay increase the serum concentration of Theophylline Derivatives.
MethohexitalMay decrease the serum concentration of Theophylline Derivatives.
MethotrexateMay increase the serum concentration of Theophylline Derivatives.
MethoxamineMay enhance the adverse/toxic effect of other Sympathomimetics.
MexiletineMay decrease the metabolism of Theophylline Derivatives.
MidodrineMay enhance the adverse/toxic effect of other Sympathomimetics.
MifepristoneMay increase the serum concentration of CYP3A4 Substrates.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
NaphazolineMay enhance the adverse/toxic effect of other Sympathomimetics.
NorepinephrineMay enhance the adverse/toxic effect of other Sympathomimetics.
OrciprenalineMay enhance the adverse/toxic effect of other Sympathomimetics.
OxymetazolineMay enhance the adverse/toxic effect of other Sympathomimetics.
PancuroniumTheophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.
Peginterferon alfa-2bMay increase the serum concentration of CYP1A2 Substrates.
PentobarbitalMay decrease the serum concentration of Theophylline Derivatives.
PentoxifyllineMay increase the serum concentration of Theophylline Derivatives.
PhenmetrazineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhentermineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenylephrineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenylpropanolamineMay enhance the adverse/toxic effect of other Sympathomimetics.
PhenytoinTheophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.
PrimidoneMay decrease the serum concentration of Theophylline Derivatives.
PropafenoneMay increase the serum concentration of Theophylline Derivatives.
PropylthiouracilMay increase the serum concentration of Theophylline Derivatives.
QuazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
QuinineMay increase the serum concentration of Theophylline Derivatives.
RegadenosonAminophylline may diminish the vasodilatory effect of Regadenoson.
RiociguatTheophylline Derivatives may enhance the hypotensive effect of Riociguat.
RitodrineMay enhance the adverse/toxic effect of other Sympathomimetics.
SalmeterolMay enhance the adverse/toxic effect of other Sympathomimetics.
SecobarbitalMay decrease the serum concentration of Theophylline Derivatives.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay decrease the serum concentration of Theophylline Derivatives. Exceptions: Fosamprenavir.
TemazepamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
TerbutalineMay enhance the adverse/toxic effect of other Sympathomimetics.
TeriflunomideMay decrease the serum concentration of CYP1A2 Substrates.
ThiabendazoleMay decrease the metabolism of Theophylline Derivatives.
ThiopentalAminophylline may diminish the therapeutic effect of Thiopental.
TiclopidineMay decrease the metabolism of Theophylline Derivatives.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TofisopamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
TriazolamTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
VemurafenibMay increase the serum concentration of CYP1A2 Substrates.
ZafirlukastTheophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives.
Food Interactions
  • Limit caffeine intake.
  • Take with food.
  • Vitamin B6 needs increased, supplement recommended.

Targets

1. cGMP-inhibited 3',5'-cyclic phosphodiesterase A

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
cGMP-inhibited 3',5'-cyclic phosphodiesterase A Q14432 Details

References:

  1. Hirota K, Yoshioka H, Kabara S, Koizumi Y, Abe H, Sato T, Matsuki A: Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Acta Anaesthesiol Scand. 2002 Mar;46(3):297-302. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Adenosine receptor A1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Adenosine receptor A1 P30542 Details

References:

  1. Yamamoto S, Nakanishi O, Matsui T, Shinohara N, Kinoshita H, Lambert C, Ishikawa T: Intrathecal adenosine A1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat. Cell Mol Neurobiol. 2003 Apr;23(2):175-85. Pubmed
  2. Lerman BB: Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation. 1993 Feb;87(2):382-90. Pubmed

3. Adenosine receptor A3

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Adenosine receptor A3 P0DMS8 Details

References:

  1. Stella L, de Novellis V, Marabese I, Berrino L, Maione S, Filippelli A, Rossi F: The role of A3 adenosine receptors in central regulation of arterial blood pressure. Br J Pharmacol. 1998 Oct;125(3):437-40. Pubmed

4. Histone deacetylase 2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Histone deacetylase 2 Q92769 Details

References:

  1. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6. Epub 2002 Jun 17. Pubmed

Enzymes

1. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13